Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8081259 | 1.00 | MCL1 (0.58) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL3553694 | 0.98 | MCL1 (0.60) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL612494 | 0.98 | MCL1 (0.60) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL17178416 | 0.95 | MCL1 (0.58) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL28677273 | 0.95 | MCL1 (0.58) | MCL1KMT2AMAPK1CA1CA2 | |
| Ethane SCHEMBL4053553 | 0.93 | MCL1 (0.56) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL932332 | 0.91 | — | — | |
| SCHEMBL22468834 | 0.91 | — | — | |
| SCHEMBL11665728 | 0.89 | MCL1 (0.53) | MCL1KMT2AMAPK1CA1CA2 | |
| Ethane SCHEMBL4051846 | 0.86 | MCL1 (0.48) | MCL1KMT2AMAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400784-A1 | Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition | LG CHEM, LTD. (KR) | 2024-12-05 | — | — | US | disclosed |
| US-20240400792-A1 | CURABLE (METH)ACRYLATE COMPOSITIONS | HENKEL AG & CO KGAA (DE) | 2024-12-05 | — | — | US | disclosed |
| US-10435645-B2 | Organoleptic compounds | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2019-10-08 | — | — | US | disclosed |
| CN-108203382-A | Novel sensory compounds | 国际香料和香精公司 | 2018-06-26 | — | — | CN | disclosed |
| US-20180171263-A1 | NOVEL ORGANOLEPTIC COMPOUNDS | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2018-06-21 | — | — | US | disclosed |
| US-20100035892-A1 | METHOD FOR ASSEMBLING HIGH-PURITY CHEMICAL LIBRARIES, COMPOUNDS SUPPRESSING ACETYL COENZYME A CARBOXYLASE ACTIVITIES DISCOVERED BY SAME | THE UNIVERSITY OF CHICAGO | 2010-02-11 | — | — | US | disclosed |
| EP-0682663-B1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2001-04-18 | — | — | EP | disclosed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| CN-1117291-A | 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections | UPJOHN CO (US) | 1996-02-21 | — | — | CN | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035892-A1 | METHOD FOR ASSEMBLING HIGH-PURITY CHEMICAL LIBRARIES, COMPOUNDS SUPPRESSING ACETYL COENZYME A CARBOXYLASE ACTIVITIES DISCOVERED BY SAME | ACACA, COASY, ACACB | MCL1 4087/4885KMT2A 2124/4885MAPK1 3995/4885 |
| US-20180171263-A1 | NOVEL ORGANOLEPTIC COMPOUNDS | TRPA1, TRPV1, TRPV5 | MCL1 3609/4885KMT2A 2395/4885MAPK1 4854/4885 |
| US-10435645-B2 | Organoleptic compounds | TRPA1, TRPV1, TRPV5 | MCL1 3855/4885KMT2A 2594/4885MAPK1 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.